» Articles » PMID: 10449779

Transgenic Mice Demonstrate AP-1 (activator Protein-1) Transactivation is Required for Tumor Promotion

Overview
Specialty Science
Date 1999 Aug 18
PMID 10449779
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Activator protein-1 (AP-1) is a transcription factor that consists of either a Jun-Jun homodimer or a Jun-Fos heterodimer. Transactivation of AP-1 is required for tumor promoter-induced transformation in mouse epidermal JB6 cells and for progression in mouse and human keratinocytes. Until now, the question of whether AP-1 transactivation is required for carcinogenesis in vivo has remained unanswered, as has the issue of functionally significant target genes. To address these issues we have generated a transgenic mouse in which transactivation mutant c-jun (TAM67), under the control of the human keratin-14 promoter, is expressed specifically in the basal cells of the epidermis where tumor induction is initiated. The keratin-14-TAM67 transgene was expressed in the epidermis, tongue, and cervix, with no apparent abnormalities in any tissue or organ. TAM67 expression blocked 12-O-tetradecanoylphorbol 13-acetate (TPA, phorbol 12-tetradecanoate 13-acetate) induction of the AP-1-regulated luciferase in AP-1 luciferase/TAM67 mice, but did not inhibit induction of candidate AP-1 target genes, collagenase-1 or stromelysin-3. More interestingly, TAM67 expression did not inhibit TPA-induced hyperproliferation. In two-stage skin carcinogenesis experiments, the transgenic animals showed a dramatic inhibition of papilloma induction. We conclude that transactivation of a subset of AP-1-dependent genes is required for tumor promotion and may be targeted for cancer prevention.

Citing Articles

Vitamin A resolves lineage plasticity to orchestrate stem cell lineage choices.

Tierney M, Polak L, Yang Y, Abdusselamoglu M, Baek I, Stewart K Science. 2024; 383(6687):eadi7342.

PMID: 38452090 PMC: 11177320. DOI: 10.1126/science.adi7342.


The CaSR Modulator NPS-2143 Reduced UV-Induced DNA Damage in Skh:hr1 Hairless Mice but Minimally Inhibited Skin Tumours.

Yang C, Rybchyn M, De Silva W, Matthews J, Dixon K, Holland A Int J Mol Sci. 2023; 24(5).

PMID: 36902353 PMC: 10002576. DOI: 10.3390/ijms24054921.


The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.

Ramchatesingh B, Martinez Villarreal A, Arcuri D, Lagace F, Setah S, Touma F Int J Mol Sci. 2022; 23(20).

PMID: 36293471 PMC: 9603842. DOI: 10.3390/ijms232012622.


Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.

Moser R, Gurley K, Nikolova O, Qin G, Joshi R, Mendez E Oncogene. 2022; 41(24):3355-3369.

PMID: 35538224 DOI: 10.1038/s41388-022-02330-w.


The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.

Casalino L, Talotta F, Cimmino A, Verde P Cancers (Basel). 2022; 14(6).

PMID: 35326630 PMC: 8946526. DOI: 10.3390/cancers14061480.


References
1.
Greenhalgh D, Wang X, Eckhardt J, Roop D . 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy. Cell Growth Differ. 1995; 6(5):579-86. View

2.
Li J, Rhim J, Schlegel R, Vousden K, Colburn N . Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene. 1998; 16(21):2711-21. DOI: 10.1038/sj.onc.1201798. View

3.
Brown K, Balmain A . Transgenic mice and squamous multistage skin carcinogenesis. Cancer Metastasis Rev. 1995; 14(2):113-24. DOI: 10.1007/BF00665795. View

4.
Takami S, Getchell M, Yamagishi M, Albers K, Getchell T . Enhanced extrinsic innervation of nasal and oral chemosensory mucosae in keratin 14-NGF transgenic mice. Cell Tissue Res. 1995; 282(3):481-91. DOI: 10.1007/BF00318880. View

5.
Li J, Dong Z, Dawson M, Colburn N . Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 1996; 56(3):483-9. View